Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions

Pharmacology Research and Perspectives

Volumn 2, Issue 1, 2014, Pages 1-12

  Nyagode, Beatrice A ^a   Jahangardi, Roya ^a   Merrell, Matthew D ^a   Tansey, Malú G ^a   Morgan, Edward T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Cytochrome P450; Drug metabolism; Drug drug interactions; Inflammation; Therapeutic proteins

Indexed keywords

CYTOCHROME P450; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; XPRO 1595;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BIOSAFETY; CENTRIFUGATION; CITROBACTER RODENTIUM; COLITIS; CONTROLLED STUDY; DENSITOMETRY; DRUG RECEPTOR BINDING; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RNA EXTRACTION; SINGLE DRUG DOSE; WESTERN BLOTTING;

EID: 84975868662     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.27     Document Type: Article

References (32)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, et al. (1993). Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44: 707-715.
2. Aitken AE, Morgan ET (2007). Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35: 1687-1693.
3. Aitken AE, Richardson TA, Morgan ET (2006). Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46: 123-149.
4. Ashino T, Oguro T, Shioda S, Horai R, Asano M, Sekikawa K, et al. (2004). Involvement of interleukin-6 and tumor necrosis factor alpha in CYP3A11 and 2C29 down-regulation by Bacillus Calmette-Guerin and lipopolysaccharide in mouse liver. Drug Metab Dispos 32: 707-714.
5. Ashino T, Arima Y, Shioda S, Iwakura Y, Numazawa S, Yoshida T (2007). Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur J Pharmacol 558: 199-207.
6. Brambilla R, Ashbaugh JJ, Magliozzi R, Dellarole A, Karmally S, Szymkowski DE, et al. (2011). Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain 134: 2736-2754.
7. Chaluvadi MR, Kinloch RD, Nyagode BA, Richardson TA, Raynor MJ, Sherman M, et al. (2009). Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of citrobacter rodentium. Drug Metab Dispos 37: 366-374.
8. Chen JQ, Strom A, Gustafsson JA, Morgan ET (1995). Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6. Mol Pharmacol 47: 940-947.
9. Dickmann LJ, Patel SK, Wienkers LC, Slatter JG (2012). Effects of interleukin 1beta (IL-1beta) and IL-1beta/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr Drug Metab 13: 930-937.
10. Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, et al. (2013). Critical review of preclinical approaches to investigate cytochrome P450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metab Dispos 41: 1598-1609.
11. Ghezzi P, Saccardo B, Bianchi M (1986a). Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. Biochem Biophys Res Commun 136: 316-321.
12. Ghezzi P, Saccardo B, Villa P, Rossi V, Bianchi M, Dinarello CA (1986b). Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect Immun 54: 837-840.
13. Goncalves NS, Ghaem-Maghami M, Monteleone G, Frankel G, Dougan G, Lewis DJ, et al. (2001). Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect Immun 69: 6651-6659.
14. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. (1995). The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802.
15. Higgins LM, Frankel G, Douce G, Dougan G, MacDonald TT (1999). Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun 67: 3031-3039.
16. Holtmann MH, Neurath MF (2004). Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 4: 439-444.
17. Kinloch RD, Lee C-M, van Rooijen N, Morgan ET (2011). Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen. Biochem Pharmacol 82: 312-321.
18. Lindberg R, Burkhart B, Ichikawa T, Negishi M (1989). The structure and characterization of type I P-450(15) alpha gene as major steroid 15 alpha-hydroxylase and its comparison with type II P-450(15) alpha gene. J Biol Chem 264: 6465-6471.
19. Ling S, Jamali F (2009). The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. Basic Clin Pharmacol Toxicol 105: 24-29.
20. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
21. Miyoshi M, Nadai M, Nitta A, Ueyama J, Shimizu A, Takagi K, et al. (2005). Role of tumor necrosis factor-alpha in down-regulation of hepatic cytochrome P450 and P-glycoprotein by endotoxin. Eur J Pharmacol 507: 229-237.
22. Morgan ET (1997). Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29: 1129-1188.
23. Morgan ET (2009). Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85: 434-438.
24. Morgan ET, Thomas KB, Swanson R, Vales T, Hwang J, Wright K (1994). Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. Biochim Biophys Acta 1219: 475-483.
25. Nyagode BA, Lee CM, Morgan ET (2010). Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon null mice. J Pharmacol Exp Ther 335: 480-488.
26. Renton KW, Singh G, Stebbing N (1984). Relationship between the antiviral effects of interferons and their abilities to depress cytochrome P-450. Biochem Pharmacol 33: 3899-3902.
27. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S (2011). Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther 89: 735-740.
28. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, et al. (2003). Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301: 1895-1898.
29. Su T, Ding X (2004). Regulation of the cytochrome P450 2A genes. Toxicol Appl Pharmacol 199: 285-294.
30. Tapner M, Liddle C, Goodwin B, George J, Farrell GC (1996). Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes. Hepatology 24: 367-373.
31. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA (1999). Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 288: 945-950.
32. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, et al. (2007). Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179: 1872-1883.